1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

        <em id="8sgz1"><label id="8sgz1"></label></em>
      2. <em id="8sgz1"><label id="8sgz1"></label></em>
        <em id="8sgz1"></em>
        <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

        <button id="8sgz1"></button>
        west china medical publishers
        Author
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Author "阿永俊" 2 results
        • Application of Artificial Liver Support System in Liver Failure and Liver Transplantation

          【Abstract】Objective To evaluate effect of artificial liver support system (ALSS) in liver failure and liver transplantation.Methods Forty-four patients with liver failure (including 12 undergoing liver transplantation) were treated with MARS or plasma exchange. The changes of toxic substances and cytokines in blood were detected before and after treatment. Results ALSS therapy achieved a remarkable improvement in clinical symptoms and physical signs. After ALSS treatment, there was a significant decrease in total bilirubin, total bile acid, alanine aminotransferase, creatinine, urea nitrogen, blood ammonia and endotoxin levels(P<0.05); the levels of serum NO, TNF-α, IL-4 and IL-6 were significantly decreased(P<0.05); there was no statistical change in erythrocytes, leukocytes and platelets. The survival rate of 30 liver failure patients caused by severe hepatitis B was 60.0%(18/30). Six patients with acute liver failure were successfully performed liver transplantation. Two patients in 6 with acute liver failure after liver transplantation survived. One patient in 2 with acute liver failure after pancreatoduodenectomy survived. Conclusion ALSS plays a positive role in treatment of liver failure by removing blood toxins, NO and cytokines. ALSS also plays a substitute role for liver failure patients who are waiting for liver transplantation.

          Release date:2016-09-08 11:54 Export PDF Favorites Scan
        • Prevention for Recurrence of Patients with Hepatitis B after Liver Transplantation

          目的探索乙型肝炎DNA陽性的終末期肝病患者肝移植前快速轉陰及肝移植術后復發的防治。方法4例乙型肝炎兩對半小三陽、HBVDNA(-)的患者術前開始聯合口服拉米夫定(lamivudine) 及泛昔洛韋, 術后3個月內治療同前, 3個月后僅口服拉米夫定維持至今; 2例乙型肝炎兩對半大三陽、HBVDNA(+)的患者, 術前除口服拉米夫定及泛昔洛韋外, 同時肌注乙肝免疫球蛋白共14 d,肝移植術中無肝期快速靜脈滴注15 000 u靜脈用乙肝免疫球蛋白,術后3個月內聯合口服拉米夫定及泛昔洛韋, 術后3個月內治療同前, 3個月后僅口服拉米夫定維持至今。結果1例患者術后第19天死于肺部霉菌感染,1例患者第49天死于肝動脈及門靜脈栓塞; 4例患者長期存活, 生存時間最長的患者已接近3年,術后全部患者均未發現有乙型肝炎復發。結論拉米夫定、乙肝免疫球蛋白及泛昔洛韋聯合使用可使乙型肝炎DNA陽性的終末期肝病患者在肝移植前快速轉陰,并能預防乙肝復發。

          Release date:2016-08-28 04:49 Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

          1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

            <em id="8sgz1"><label id="8sgz1"></label></em>
          2. <em id="8sgz1"><label id="8sgz1"></label></em>
            <em id="8sgz1"></em>
            <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

            <button id="8sgz1"></button>
            欧美人与性动交α欧美精品